Collegium Pharmaceutical reported quarterly EPS of $1.76, beating the Zacks Consensus Estimate of $1.42 by $0.34 per share, and improving from $1.49 a year ago. The result is a positive earnings surprise with modest year-over-year growth, supportive for the stock but not a major catalyst on its own.
Collegium Pharmaceutical reported quarterly EPS of $1.76, beating the Zacks Consensus Estimate of $1.42 by $0.34 per share, and improving from $1.49 a year ago. The result is a positive earnings surprise with modest year-over-year growth, supportive for the stock but not a major catalyst on its own.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.45
Ticker Sentiment
